Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study.
Sam SchulmanVanessa CarlsonPablo Emilio SerranoNiv SneKamyar KahnamouiSiraj MithoowaniRick IkesakaPeter L GrossPublished in: Journal of surgical oncology (2022)
Our results support good adherence with apixaban for VTE prophylaxis up to 28 days after major abdominal or pelvic cancer surgery.
Keyphrases